Recent Scientific Publications

Association of Vascular Risk Factors and Cerebrovascular Pathology with Alzheimer Disease Pathologic Changes in Individuals Without Dementia 

• Date October 8^th  2024
• Presentation type: co-authored journal manuscript with the AMYPAD consortium in the journal Neurology
• Synopsis: investigation of links between vascular risk factors, cerebral small vessel disease, and amyloid levels and their combined effect on downstream AD biomarkers.
• Therapeutic Indication: Alzheimer’s disease (AD)

A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial.

• Date: October 31^st 2024
• Presentation type: oral presentation at the 17^th Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid, Spain.
• Synopsis: analysis of the Global Alzheimer’s Platform Bio-Hermes data to investigate how blood-based-biomarkers can be operationalised in conjunction with PET imaging.
• Therapeutic Indication: Alzheimer’s disease (AD)

Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study

• Date: January 2025
• Presentation type: co-authored journal manuscript with the AMYPAD consortium in The Journal of Nuclear Medicine
• Synopsis: analysis of the AMYPAD study data that shows how automated quantitative analysis of amyloid PET data can support and streamline visual expert assessment.
• Therapeutic Indication: Alzheimer’s disease (AD)

Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials

• Date: 25^th February 2025
• Presentation type: poster presentation at the 20^th Annual HD Therapeutics Conference in Palm Springs, CA.
• Synopsis: analysis of data from the HD-IH consortium to show that external control groups can support regulatory decision-making in clinical trials, especially rare diseases like Huntington’s disease (HD).
• Therapeutic Indication: Huntington’s disease (HD)

The Potential of Blood-Based Biomarkers & Digital Assessments in Transforming Research and Clinical Practice

• Date: February 26^th 2025
• Presentation type: invited podium presentation and discussion at the GAP-Net Site Optimization Conference 2025
• Synopsis: invited presentation to discuss the critical role of imaging in an evolving AD biomarker landscape, specifically in combination with novel blood based biomarker tests. Joint panel with C-level experts from diagnostics and pharma companies.
• Therapeutic Indication: Alzheimer’s disease (AD)

Neuroimaging Biomarkers for Friedreich Ataxia: A Cross-Sectional Analysis of the TRACK-FA Study

• Date: March 22^nd 2025
• Presentation type: co-authored journal manuscript with the TRACK-FA consortium in the Annals of Neurology Journal
• Synopsis: development and validation of novel brain and spinal cord volumetric biomarkers for Friedreich’s Ataxia as part of the TRACK-FA study.
• Therapeutic Indication: Friedreich’s Ataxia (FA)

AI-Driven Classification of Alzheimer’s Disease and Frontotemporal Dementia from Magnetic Resonance Imaging

• Date: April 4^th 2025
• Presentation type: oral presentation at the 40^th International Conference on Alzheimer’s Disease and Parkinson’s Disease (ADPD) in Vienna, Austria
• Synopsis: development and validation of novel AI-driven measurements to support differential diagnosis between AD and FTD from volumetric MRI.
• Therapeutic Indication: Alzheimer’s disease (AD); Frontotemporal dementia (FTD)

Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis

• Date: April 17^th 2025
• Presentation type: invited editorial in the Journal for Clinical Studies
• Synopsis: editorial discussion on the multimodal use of PET imaging in combination with novel blood based biomarkers to support streamlined clinical trial delivery.
• Therapeutic Indication: Alzheimer’s disease (AD)

AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Dataset

• Date: 28^th July 2025
• Presentation type: poster presentation at the Alzheimer’s Association International Conference 2025 in Toronto, Canada
• Synopsis: embargoed
• Therapeutic Indication: Alzheimer’s disease (AD)